ADVFN Logo ADVFN

No pudimos encontrar ningún resultado para:
Asegúrate de que la ortografía sea correcta o intenta ampliar tu búsqueda.

Tendencias Ahora

Listas Principales

Parece que no has iniciado sesión.
Haz clic en el botón de abajo para iniciar sesión y ver tu historial reciente.

Hot Features

Registration Strip Icon for default Regístrate gratis para obtener cotizaciones en tiempo real, gráficos interactivos, flujo de opciones en vivo y más.

INVA Innoviva Inc

16.16
0.25 (1.57%)
17 Jun 2024 - Cerrado
Retrasado por 15 minutos
Nombre de la Acción Símbolo de la Acción Bolsa de Valores Tipo de Valor
Innoviva Inc INVA NASDAQ Acción Común
  Variación del Día (ptos.) Variación del Día (%) Último Precio Hora
0.25 1.57% 16.16 17:06:53
Precio de Apertura Precio Mínimo Precio Máximo Precio de cierre Precio Anterior
15.85 15.85 16.345 16.16 15.91
más cotizaciones de acciones »

Noticias Recientes

Fecha Hora Fuente Noticia
03/6/202406:00BWInnoviva to Participate in the Goldman Sachs 45th Annual..
21/5/202419:15EDGAR2Form 4 - Statement of changes in beneficial ownership of..
21/5/202419:13EDGAR2Form 4 - Statement of changes in beneficial ownership of..
13/5/202408:27EDGAR2Form 8-K - Current report
08/5/202415:46EDGAR2Form 10-Q - Quarterly report [Sections 13 or 15(d)]
08/5/202415:44EDGAR2Form 8-K - Current report
08/5/202415:05BWInnoviva Reports First Quarter 2024 Financial Results;..
08/5/202406:00BWInnoviva to Participate in the BofA Securities Health Care..
24/4/202406:00BWInnoviva Specialty Therapeutics’ Positive Phase 3 Oral..
07/3/202418:04EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202418:02EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202418:00EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07/3/202417:57EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29/2/202416:01EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
29/2/202415:15EDGAR2Form 8-K - Current report
29/2/202415:05BWInnoviva Reports Fourth Quarter and Full Year 2023 Financial..
22/2/202420:31EDGAR2Form 4 - Statement of changes in beneficial ownership of..
22/2/202420:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
14/2/202406:23EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
22/1/202420:16EDGAR2Form 4 - Statement of changes in beneficial ownership of..
10/1/202419:26EDGAR2Form 3 - Initial statement of beneficial ownership of..
17/11/202315:30EDGAR2Form 4 - Statement of changes in beneficial ownership of..
06/11/202307:30EDGAR2Form 8-K - Current report
01/11/202315:30EDGAR2Form 8-K - Current report
01/11/202315:15BWInnoviva Reports Third Quarter 2023 Financial Results and..
01/11/202315:05BWPositive Results Announced in Largest Pivotal Phase 3 Trial..
19/9/202307:30BWInnoviva to Participate in the Cantor Global Healthcare..
18/9/202307:00BWXACDURO®, The First and Only Antibiotic Developed to Target..
31/8/202319:12EDGAR2Form 4 - Statement of changes in beneficial ownership of..
31/8/202312:58EDGAR2Form 4 - Statement of changes in beneficial ownership of..
25/8/202316:24EDGAR2Form 8-K - Current report
25/8/202315:52BWInnoviva Appoints Stephen Basso as Chief Financial Officer
07/8/202315:42EDGAR2Form 8-K - Current report
02/8/202320:32EDGAR2Form 4 - Statement of changes in beneficial ownership of..
02/8/202315:15EDGAR2Form 8-K - Current report
02/8/202315:05BWInnoviva Reports Second Quarter 2023 Financial Results and..
11/7/202307:16EDGAR2Form 8-K - Current report

Su Consulta Reciente

Delayed Upgrade Clock